CD79A and psoriasis: Anyway, studies on GFD in patients with psoriasis showed a clinical benefit in terms of disease control only for those with CD; for example, Michaëlsson et al. showed that adult patients with psoriasis and positivity for antigliadin IgA or IgG had a significant PASI score decrease after three months of GFD (reduction in PASI from 5.5 ± 4.5 to 3.6 ± 3.0); after returning to a non-GFD, 60% of patients had worsening of psoriasis symptoms.